1014 related articles for article (PubMed ID: 15198717)
1. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
Hasegawa R; Koizumi M; Hirose A
Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
[TBL] [Abstract][Full Text] [Related]
2. Precision of estimates of an ADI (or TDI or PTWI).
Speijers GJ
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
[TBL] [Abstract][Full Text] [Related]
3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
4. Background to the ADI/TDI/PTWI.
Herrman JL; Younes M
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
[TBL] [Abstract][Full Text] [Related]
5. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
6. Derivation of Biomonitoring Equivalents for di(2-ethylhexyl)phthalate (CAS No. 117-81-7).
Aylward LL; Hays SM; Gagné M; Krishnan K
Regul Toxicol Pharmacol; 2009 Dec; 55(3):249-58. PubMed ID: 19751789
[TBL] [Abstract][Full Text] [Related]
7. Probabilistic risk characterization: an example with di(2-ethylhexyl) phthalate.
Bosgra S; Bos PM; Vermeire TG; Luit RJ; Slob W
Regul Toxicol Pharmacol; 2005 Oct; 43(1):104-13. PubMed ID: 16099565
[TBL] [Abstract][Full Text] [Related]
8. The use of an additional safety or uncertainty factor for nature of toxicity in the estimation of acceptable daily intake and tolerable daily intake values.
Renwick AG
Regul Toxicol Pharmacol; 1995 Dec; 22(3):250-61. PubMed ID: 8837849
[TBL] [Abstract][Full Text] [Related]
9. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
[TBL] [Abstract][Full Text] [Related]
10. An analysis of the risk of exceeding the acceptable or tolerable daily intake.
Renwick AG; Walker R
Regul Toxicol Pharmacol; 1993 Dec; 18(3):463-80. PubMed ID: 8128007
[TBL] [Abstract][Full Text] [Related]
11. Derivation of Biomonitoring Equivalents for di-n-butyl phthalate (DBP), benzylbutyl phthalate (BzBP), and diethyl phthalate (DEP).
Aylward LL; Hays SM; Gagné M; Krishnan K
Regul Toxicol Pharmacol; 2009 Dec; 55(3):259-67. PubMed ID: 19751787
[TBL] [Abstract][Full Text] [Related]
12. Procedures for calculating benchmark doses for health risk assessment.
Gaylor D; Ryan L; Krewski D; Zhu Y
Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
[TBL] [Abstract][Full Text] [Related]
13. Methods for deriving pesticide aquatic life criteria.
TenBrook PL; Tjeerdema RS; Hann P; Karkoski J
Rev Environ Contam Toxicol; 2009; 199():19-109. PubMed ID: 19110939
[TBL] [Abstract][Full Text] [Related]
14. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects.
Shipp A; Lawrence G; Gentry R; McDonald T; Bartow H; Bounds J; Macdonald N; Clewell H; Allen B; Van Landingham C
Crit Rev Toxicol; 2006; 36(6-7):481-608. PubMed ID: 16973444
[TBL] [Abstract][Full Text] [Related]
15. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
Cosmetic Ingredient Review Expert Panel
Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
[TBL] [Abstract][Full Text] [Related]
16. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
Müller L; Gocke E
Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
[TBL] [Abstract][Full Text] [Related]
17. The significance of excursions above the ADI: duration in relation to pivotal studies.
Walker R
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S114-8. PubMed ID: 10597624
[TBL] [Abstract][Full Text] [Related]
18. A dose response study following in utero and lactational exposure to di-(2-ethylhexyl) phthalate (DEHP): reproductive effects on adult male offspring rats.
Andrade AJ; Grande SW; Talsness CE; Gericke C; Grote K; Golombiewski A; Sterner-Kock A; Chahoud I
Toxicology; 2006 Nov; 228(1):85-97. PubMed ID: 16996189
[TBL] [Abstract][Full Text] [Related]
19. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
Dorne JL
Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
[TBL] [Abstract][Full Text] [Related]
20. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points.
Bogen KT; Gold LS
Regul Toxicol Pharmacol; 1997 Feb; 25(1):26-42. PubMed ID: 9056499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
